NovImmune has currently seven promising monoclonal antibodies for the treatment of immune-related disorders in its pipeline with a balance of clinical and preclinical compounds. The most advanced is in clinical development phase II.
Each product, driven by its mechanism of action, has the potential to ultimately become a medicine for multiple diseases. Our lead product, NI-0401/anti-CD3 is already explored in Crohn’s disease, Type 1 diabetes, and transplantation.

Find out more about each of our products by clicking on it in the image below.

Product	Indication	Research	Pre-Clinical	Phase I	Phase II	Phase III
NI-0401/α-CD3	T1D
NI-0401/α-CD3	CD
NI-0401/α-CD3	Tx
NI-0801/α-IP-10	AIID
NI-0501/α-IFNγ	AIID
NI-0701/α-RANTES	AIID
NI-1401/α-IL-17	AIID
NI-0101/α-TLR4	AIID
NI-1201/α-IL-6Rc	AIID

Acronyms:
T1D: Type 1 Diabetes
CD: Crohn's Disease
TX: Transplantation
AIID: Auto-Immune and Inflammatory Diseaseas